tetano
Editor, Senior Moderator
Brain Dev
. 2023 Sep 1;S0387-7604(23)00147-X.
doi: 10.1016/j.braindev.2023.08.006. Online ahead of print. Febrile seizure in children with COVID-19 during the Omicron variant-predominant era: A single-center study
Kento Ohta[SUP] 1 [/SUP], Tohru Okanishi[SUP] 2 [/SUP], Yuto Arai[SUP] 1 [/SUP], Sotaro Kanai[SUP] 1 [/SUP], Yuko Nakamura[SUP] 1 [/SUP], Noriyuki Namba[SUP] 3 [/SUP], Yoshihiro Maegaki[SUP] 1 [/SUP]
Affiliations
Objective: Coronavirus disease 2019 (COVID-19) has significantly impacted medical services worldwide. During the Omicron variant-predominant era, febrile seizure (FS) in patients with COVID-19 increased compared to that in the pre-Omicron variant era. Therefore, this study aimed to demonstrate the clinical characteristics of FS in patients with COVID-19.
Methods: We surveyed patients aged < 16 years who presented with FS to the emergency room of Tottori University Hospital. The patients were divided into two groups: FS patients with COVID-19 (FS with COVID-19 group) and FS patients without COVID-19 (FS without COVID-19 group) as per the results of the respiratory multiplex array test. Patients with positive results for both SARS-CoV-2 and other microorganisms were excluded. We obtained data on the patients' clinical backgrounds, symptoms, seizure duration, type of FS (simple or complex), diagnostic examinations, laboratory test results, and treatment. We compared the data between the FS with and without COVID-19 groups.
Result: A total of 128 patients with FS met the inclusion criteria. Of these, 18 patients and 110 patients were included in the FS with COVID-19 group and without COVID-19 group, respectively. The late FS onset (>60 months) were significantly more common in the FS with COVID-19 group than that in the FS without COVID-19 group. Moreover, patients in the FS with COVID-19 group had significantly longer seizure durations than those in the FS without COVID-19 group. A diazepam (DZP) suppository was administered to 72% of FS patients with COVID-19 after the first seizure during a febrile episode.
Conclusion: FS patients with COVID-19 had different distributions of age at onset and seizure duration than those without COVID-19. The use of DZP suppositories was more frequent in FS patients with COVID-19 compared to those without COVID-19.
Keywords: Coronavirus disease 2019; Diazepam; Febrile seizure; Prolonged seizure; Severe acute respiratory syndrome coronavirus 2.
. 2023 Sep 1;S0387-7604(23)00147-X.
doi: 10.1016/j.braindev.2023.08.006. Online ahead of print. Febrile seizure in children with COVID-19 during the Omicron variant-predominant era: A single-center study
Kento Ohta[SUP] 1 [/SUP], Tohru Okanishi[SUP] 2 [/SUP], Yuto Arai[SUP] 1 [/SUP], Sotaro Kanai[SUP] 1 [/SUP], Yuko Nakamura[SUP] 1 [/SUP], Noriyuki Namba[SUP] 3 [/SUP], Yoshihiro Maegaki[SUP] 1 [/SUP]
Affiliations
- PMID: 37661526
- DOI: 10.1016/j.braindev.2023.08.006
Objective: Coronavirus disease 2019 (COVID-19) has significantly impacted medical services worldwide. During the Omicron variant-predominant era, febrile seizure (FS) in patients with COVID-19 increased compared to that in the pre-Omicron variant era. Therefore, this study aimed to demonstrate the clinical characteristics of FS in patients with COVID-19.
Methods: We surveyed patients aged < 16 years who presented with FS to the emergency room of Tottori University Hospital. The patients were divided into two groups: FS patients with COVID-19 (FS with COVID-19 group) and FS patients without COVID-19 (FS without COVID-19 group) as per the results of the respiratory multiplex array test. Patients with positive results for both SARS-CoV-2 and other microorganisms were excluded. We obtained data on the patients' clinical backgrounds, symptoms, seizure duration, type of FS (simple or complex), diagnostic examinations, laboratory test results, and treatment. We compared the data between the FS with and without COVID-19 groups.
Result: A total of 128 patients with FS met the inclusion criteria. Of these, 18 patients and 110 patients were included in the FS with COVID-19 group and without COVID-19 group, respectively. The late FS onset (>60 months) were significantly more common in the FS with COVID-19 group than that in the FS without COVID-19 group. Moreover, patients in the FS with COVID-19 group had significantly longer seizure durations than those in the FS without COVID-19 group. A diazepam (DZP) suppository was administered to 72% of FS patients with COVID-19 after the first seizure during a febrile episode.
Conclusion: FS patients with COVID-19 had different distributions of age at onset and seizure duration than those without COVID-19. The use of DZP suppositories was more frequent in FS patients with COVID-19 compared to those without COVID-19.
Keywords: Coronavirus disease 2019; Diazepam; Febrile seizure; Prolonged seizure; Severe acute respiratory syndrome coronavirus 2.